Ipsen and Oncodesign in second Parkinson's deal
This article was originally published in Scrip
Executive Summary
Building on an earlier deal in January, the drug discovery company and oncology pharmacology service provider, Oncodesign, along with the laboratory for neurobiology and gene therapy at the department of neurosciences at the Catholic University in Leuven, have entered into a new research collaboration to evaluate, with Ipsen, Oncodesign's compounds in multiple pharmacology models for Parkinson's disease.